EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sodium Alendronate-Modified PLGA-mPEG Nanomicelles Loaded with Rifapentine for Targeted Delivery to Bone Tissue

Weilin Wang, Xin Cui, Hengfa Wei, Jingjing Wang, Yesbolat Ahehati, Cuiping Jiang, Fei Li, Shasha Li

Pharmaceutics · 12.03.2026 · 18 (3) · 352

DOI: 10.3390/pharmaceutics18030352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 12.03.2026. Verfasst von Weilin Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, College of Pharmacy, Xinjiang Medical Univ…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Xinjiang Uygur Autonomous Region, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The limited targeting efficiency and systemic toxicity of conventional medicine present significant challenges in the treatment of skeletal disorders, such as bone tuberculosis. To address these limitations, we developed a bone-targeting nanomicelle delivery system functionalized with alendronate (ALN), designated ALN-PLGA-mPEG@RPT, to improve the targeted delivery and therapeutic efficacy of rifapentine (RPT) in bone tissue.

Methods

The ALN-PLGA-mPEG blank micelles, prepared in accordance with our research group’s optimized protocol, were loaded with RPT and subjected to systematic formulation optimization. The resulting nanomicellar system was comprehensively characterized in terms of its physicochemical properties, including particle size and polydispersity index (PDI). Additionally, drug-loading capacity, encapsulation efficiency, and in vitro release curve were evaluated. Bone-targeting efficacy was assessed using in vivo imaging techniques, while biodistribution and safety profiles were determined through in vivo distribution studies and histopathological examination.

Results

The optimized ALN-PLGA-mPEG@RPT nanomicelles exhibited a mean particle size of 101.90 ± 4.17 nm, and a PDI of 0.242 ± 0.021. The formulation achieved a drug loading of 16.74 ± 0.51% with an encapsulation efficiency of 50.27 ± 1.91%. In vitro release studies confirmed a sustained-release profile, with only 25% of RPT released within 12 h. In vivo imaging revealed significantly enhanced bone-targeting capability in the ALN-modified group, showing a 1.93-fold higher drug accumulation in bone tissue compared to blood. Histopathological analysis indicated no observable pathological alterations in major organs.

Conclusions

The ALN-PLGA-mPEG@RPT nanomicelle system exhibits favorable bone-targeting efficiency, sustained-release properties, and biocompatibility, representing a promising strategy for the precise treatment of bone tuberculosis and other skeletal diseases.

Schlagwörter

Stichwörter der Autor:innen

bisphosphonatesbone targetingdrug delivery systempolymeric micellesrifapentine

Autor:innen und Institutionen

  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, College of Pharmacy, Xinjiang Medical University, Urumqi 830054, China.
  • Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China.
  • State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
  • Xinjiang Key Laboratory of Natural Medicines Active Components and Drug Release Technology, Urumqi 830054, China.

Förderung

  • Natural Science Foundation of Xinjiang Uygur Autonomous Region
  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia

Zitieren

APA

Wang, W., Cui, X., Wei, H., Wang, J., Ahehati, Y., Jiang, C., Li, F., & Li, S. (2026). Sodium Alendronate-Modified PLGA-mPEG Nanomicelles Loaded with Rifapentine for Targeted Delivery to Bone Tissue. Pharmaceutics, 18(3), 352. https://doi.org/10.3390/pharmaceutics18030352

Vancouver

Wang W, Cui X, Wei H, Wang J, Ahehati Y, Jiang C, et al. Sodium Alendronate-Modified PLGA-mPEG Nanomicelles Loaded with Rifapentine for Targeted Delivery to Bone Tissue. Pharmaceutics. 2026;18(3):352. doi:10.3390/pharmaceutics18030352

BibTeX
@article{Wang2026,
  author = {Wang, Weilin and Cui, Xin and Wei, Hengfa and Wang, Jingjing and Ahehati, Yesbolat and Jiang, Cuiping and Li, Fei and Li, Shasha},
  title = {Sodium Alendronate-Modified PLGA-mPEG Nanomicelles Loaded with Rifapentine for Targeted Delivery to Bone Tissue},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {352},
  doi = {10.3390/pharmaceutics18030352}
}
Kostenlos starten →